Living With Disease

Patient Perspectives

When you think of the word ‘cancer,’ what are the first words that spring to mind?

Fighter. Hero. Cancer-stricken. The words and metaphors people use to talk about cancer often feel worlds apart from any other disease. But how far does it go? Do words matter?

CancerDisease AwarenessLiving With DiseaseOncology
Novartis Entresto® granted expanded indication in chronic heart failure by FDA

Basel, February 16, 2021 — Novartis today announced that the US Food and Drug Administration (FDA) has approved the following expanded indication for Entresto® (sacubitril/valsartan): to reduce the risk of cardiovascular death and hospitalization for heart failure in adult patients with chronic heart failure1. Benefits are most clearly evident in…

Reimagine MedicineNeuroscienceMedical InnovationsLiving With Disease
Access to Healthcare

Breaking down barriers for patients with sickle cell disease

One patient’s story reveals the hidden obstacles to better health – and opportunities to help clear them.

Access to HealthcareDisease AwarenessGenetic DiseaseLiving With DiseasePatient Voices
Sound Up for Lung Cancer

It’s time to change the conversation. Patient inspired and community led, Sound Up aims to empower people affected by lung cancer in raising the volume to vocally self-advocate.

CancerLiving With DiseaseOncologyPatient VoicesSocial Commitment
AveXis Announces Alignment with FDA on Next Steps Toward a BLA Submission for AVXS-101 in SMA Type 1

AveXis Announces Alignment with FDA on Next Steps Toward a BLA Submission for AVXS-101 in SMA Type 1

Reimagine MedicineNovartis Gene TherapiesLiving With Disease
REGENXBIO and AveXis Announce Expansion of Relationship through Amended License Agreement for the Development and Commercialization of Treatments for Spinal Muscular Atrophy

REGENXBIO and AveXis Announce Expansion of Relationship through Amended License Agreement for the Development and Commercialization of Treatments for Spinal Muscular Atrophy

Reimagine MedicineNovartis Gene TherapiesLiving With Disease
AveXis Announces Expanded Clinical Development Program for AVXS-101 in Spinal Muscular Atrophy

AveXis Announces Expanded Clinical Development Program for AVXS-101 in Spinal Muscular Atrophy

Reimagine MedicineNovartis Gene TherapiesLiving With Disease
AveXis Announces Proposed Public Offering of Common Stock

AveXis Announces Proposed Public Offering of Common Stock

Reimagine MedicineNovartis Gene TherapiesLiving With Disease
AveXis Announces Pricing of Public Offering of Common Stock

AveXis Announces Pricing of Public Offering of Common Stock

Reimagine MedicineNovartis Gene TherapiesLiving With Disease
AveXis Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares

AveXis Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares

Reimagine MedicineNovartis Gene TherapiesLiving With Disease
AveXis to Initiate Screening for Remaining Patients in Pivotal Trial of AVXS-101 for SMA Type 1 Following Review of Preliminary Data from First Three Patients

AveXis to Initiate Screening for Remaining Patients in Pivotal Trial of AVXS-101 for SMA Type 1 Following Review of Preliminary Data from First Three Patients

Reimagine MedicineNovartis Gene TherapiesLiving With Disease
AveXis to Report Fourth Quarter and Full Year 2017 Financial and Operating Results

AveXis to Report Fourth Quarter and Full Year 2017 Financial and Operating Results

Reimagine MedicineNovartis Gene TherapiesLiving With Disease